HCPLive published a segment on Tuesday featuring Hisamitsu Hayashi, PhD, focused on how treatment for progressive familial intrahepatic cholestasis (PFIC) can be aimed at the disease mechanism itself. The discussion was released under the outlet's reporting on PFIC care, according to HCPLive.
The segment centers on the idea of directing therapy at the biological process behind the condition rather than only managing its symptoms. HCPLive identifies Hayashi as the featured expert in the discussion.
PFIC refers to a group of inherited liver disorders that disrupt the flow of bile, though the source material does not include further clinical detail on the condition or on specific therapies. The published item is a headline and summary only, with no full article text available.
The segment adds to HCPLive's ongoing coverage of liver disease and treatment strategy. No specific findings, data, or recommendations from Hayashi were included in the available material.
What to watch next: whether HCPLive publishes fuller reporting from the discussion, including any details on mechanism-targeted approaches and how they might apply in practice.
